CervoMed is a public, Boston, MA-based company advancing CNS-focused therapeutics to benefit patients with neurodegenerative diseases. CervoMed was launched in 2014 as EIP Pharma, Inc, by R&D executives from the pharmaceutical and biotech industry. In August, 2023 EIP Pharma merged with Diffusion Pharmaceuticals, retaining EIP’s development pipeline, but changing their name to CervoMed (CRVO). For more information about the company and updates, please visit www.cervomed.com/ or follow us on Twitter at @Cervo_Med.
| Website | http://www.cervomed.com |
| Employees | 20 (14 on RocketReach) |
| Founded | 2023 |
| Address | 20 Park Plaza, Boston, Massachusetts 02116, US |
| Phone | +1 617-744-4400 |
| Industry | Pharmaceutical Manufacturing |
| Keywords | Neurodegenerative Diseases, Cns Therapeutics, Pharmaceutical Research, Biotech Research, Drug Development, Clinical Trials, Therapeutics, Neurology, Biotechnology, Medicine, Patient Care, Health, Research And Development, Treatment, Central Nervous System, Brain Health, Cognitive Disorders, Neurological Disorders, Alzheimers |
| Competitors | Catalyst Pharmaceuticals, Inc., Hemispherx Biopharma, Inc., Eton Pharmaceuticals, Inc, Spectrum Pharmaceuticals, CytoDyn, Axovant Sciences Ltd, Tonix Pharmaceuticals, Ovid Therapeutics, X4 Pharmaceuticals, Zynerba Pharmaceuticals +42 more (view full list) |
Looking for a particular CervoMed employee's phone or email?
John Alam is the CEO and Member of the Board of CervoMed.
14 people are employed at CervoMed.
CervoMed is based in Boston, Massachusetts.